Ms. Namrata Malhotra reports

HELIX BIOPHARMA CORP. REPORTS VOTING RESULTS

Helix BioPharma Corp. has released the voting results of the company's annual general meeting of shareholders held on Jan. 18, 2024.

There were 34 shareholders represented in person or by proxy at the meeting holding 94,199,707 common shares, representing approximately 43.48 per cent of Helix's total issued and outstanding shares. Below is a summary of the results of matters voted on at the meeting.

1. Election of directors

Each of the nominees for election as directors listed in Helix's management information circular dated Dec. 18, 2023, was elected as a director of Helix for the ensuing year or until their successors are elected or appointed. Management received proxies in respect of the election of directors of Helix as noted herein.

2. Appointment of auditor

Clearhouse LP was appointed auditor of Helix until the next annual meeting of shareholders at remuneration to be fixed by the directors. Management received proxies in respect of the appointment of the auditor of Helix as noted herein.

3. Proposed consolidation

The proposed amendment to the articles of the company to provide that the authorized capital of the company be altered by consolidating all of the issued and outstanding shares on the basis of a ratio to be determined by the board, in its sole discretion, within a range of one postconsolidation common share for up to 20 preconsolidation was approved.

Management received proxies in respect of the proposed consolidation of common shares of Helix as noted herein.

About Helix BioPharma Corp.

Helix BioPharma is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47.

We seek Safe Harbor.